Reply to Harrington et al.
作者信息
Sidharthan Sreetha, Kohli Anita, Kottilil Shyam
机构信息
Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda.
Institute of Human Virology, University of Maryland, Baltimore Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
出版信息
Clin Infect Dis. 2015 Aug 15;61(4):667-8. doi: 10.1093/cid/civ403. Epub 2015 May 22.
Abstract
摘要
相似文献
1
Reply to Harrington et al.
Clin Infect Dis. 2015 Aug 15;61(4):667-8. doi: 10.1093/cid/civ403. Epub 2015 May 22.
2
Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.
Clin Infect Dis. 2015 Aug 15;61(4):666-7. doi: 10.1093/cid/civ402. Epub 2015 May 22.
3
Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection.
J Viral Hepat. 2010 Dec;17(12):896. doi: 10.1111/j.1365-2893.2009.01256.x.
4
Twelve week post-treatment undetectable hepatitis C virus (HCV)-RNA by PCR assay predicts a sustained virological response to anti-HCV therapy independently from immunological status of the infected patients.
J Antimicrob Chemother. 2013 Apr;68(4):974-5. doi: 10.1093/jac/dks485. Epub 2012 Dec 5.
5
[Peginterferon-alfa-2b or -alfa-2a and ribavirin combined treatment in hepatitis C infection].
Orv Hetil. 2010 Feb 14;151(7):271-3. doi: 10.1556/OH.2010.28801.
6
Adverse events raise concerns over safety of new hepatitis C drugs.
BMJ. 2017 Jan 29;356:j490. doi: 10.1136/bmj.j490.
7
Ribavirin therapeutic drug monitoring: why, when and how?
Fundam Clin Pharmacol. 2010 Aug;24(4):401-6. doi: 10.1111/j.1472-8206.2009.00778.x. Epub 2009 Sep 24.
8
Virology: fresh assault on hepatitis C.
Nature. 2003 Nov 13;426(6963):129-31. doi: 10.1038/nature02105.
9
The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus.
Infect Dis Clin North Am. 2012 Dec;26(4):879-91. doi: 10.1016/j.idc.2012.08.007.
10
[Genotype 1 superresponder treat for only 24 weeks].
MMW Fortschr Med. 2005 Dec 15;147(51-52):69.
引用本文的文献
1
Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies.
Therap Adv Gastroenterol. 2017 Jan;10(1):68-73. doi: 10.1177/1756283X16672392. Epub 2016 Oct 17.
本文引用的文献
1
Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.
Clin Infect Dis. 2015 Aug 15;61(4):666-7. doi: 10.1093/cid/civ402. Epub 2015 May 22.
2
Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.
Clin Infect Dis. 2015 Jun 15;60(12):1743-51. doi: 10.1093/cid/civ170. Epub 2015 Mar 2.
3
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet. 2014 Aug 2;384(9941):403-13. doi: 10.1016/S0140-6736(14)60494-3. Epub 2014 Jun 4.
4
Boceprevir for untreated chronic HCV genotype 1 infection.
N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494.
5
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
Gastroenterology. 2008 Aug;135(2):451-8. doi: 10.1053/j.gastro.2008.04.015. Epub 2008 May 27.
Zotero 插件